Alexza Announces Resubmission of AZ-004 NDA

Alexza Pharmaceuticals, Inc. ALXA announced today that it has resubmitted its AZ-004 New Drug Application to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Lette received in October 2010. The Company believes this is a Class 2 resubmission with a six-month review cycle. AZ-004 is being developed for the rapid treatment of agitation in schizophrenia or bipolar disorder patients.